Aeterna Zentaris tanks on FDA Macrilen rejection
This article was originally published in Scrip
Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).
You may also be interested in...
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.